Clinical trials
Recurrence trials in Finland
Search ClinicalTrials.gov registrations by keyword, then narrow by condition, phase, status, country and start year.
49 trials match Source: ClinicalTrials.gov registrations
Trials started per year
By phase, 2000 to 2026.
| Category | Trials |
|---|---|
| 2001 | 3 |
| 2003 | 2 |
| 2004 | 1 |
| 2005 | 3 |
| 2008 | 1 |
| 2009 | 2 |
| 2010 | 2 |
| 2012 | 2 |
| 2015 | 1 |
| 2016 | 2 |
| 2017 | 2 |
| 2018 | 6 |
| 2019 | 3 |
| 2020 | 3 |
| 2021 | 2 |
| 2022 | 2 |
| 2023 | 1 |
| 2024 | 2 |
| 2025 | 8 |
Status
Trials by registry status. Select a bar to filter.
| Category | Trials |
|---|---|
| Completed | 25 |
| Recruiting | 11 |
| Unknown status | 7 |
| Active, not recruiting | 4 |
| Terminated | 2 |
Top lead sponsors
A sponsor with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Celgene | 5 |
| Novartis Pharmaceuticals | 4 |
| Turku University Hospital | 4 |
| Helsinki University Central Hospital | 3 |
| Kuopio University Hospital | 3 |
| Princess Maxima Center for Pediatric Oncology | 3 |
| AbbVie | 2 |
| Amgen | 2 |
| Pfizer | 2 |
| Amsterdam UMC, location VUmc | 1 |
Top conditions
MeSH conditions the trials were registered with, not their broader categories. A condition with a page on Pharma Observatory links to it.
| Category | Trials |
|---|---|
| Recurrence | 49 |
| Multiple Myeloma | 9 |
| Neoplasms | 7 |
| Leukemia | 5 |
| Precursor Cell Lymphoblastic Leukemia-Lymphoma | 5 |
| Breast Neoplasms | 4 |
| Leukemia, Myeloid, Acute | 4 |
| Lymphoma, Large B-Cell, Diffuse | 4 |
| Lymphoma, Non-Hodgkin | 4 |
| Precursor T-Cell Lymphoblastic Leukemia-Lymphoma | 4 |
Trials
Showing 26 to 49 of 49. Each trial links to its page on Pharma Observatory.
Recently changed trials
Changes observed in the last 7 days, newest first, site-count changes left out. Source: ClinicalTrials.gov.
No changes to these trials in the last 7 days.
Go deeper on Pharma Observatory
Pharma Observatory connects clinical trials, sponsors, sites and investigators in one searchable platform.